Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2017

View Archived Issues

FDA grants fast track designation to Sequoia's vaccine for recurrent urinary tract infections

Orphan drug designation for Ascend Biopharmaceuticals' ASN-002

Alexion announces R&D realignment strategy, terminates partnerships

Mount Tam Biotechnologies enters into collaboration to explore drugs in Parkinson's disease

Siliq injection launched in the U.S. for the treatment of adults with plaque psoriasis

Advanced Accelerator Applications resubmits NDA in U.S. for Lutathera

Proteros and Janssen Biotech enter collaboration agreement

Chugai Pharmaceutical reviews highlights of second quarter 2017

Quark Pharmaceuticals reports positive results from QPI-1002 phase II study

FCN3 gene polymorphisms tied to viral hepatitis in HIV patients

Akcea and Ionis submit MAA in Europe for volanesorsen

VenatoRx Pharmaceuticals receives funding for new class of antibiotic

EC approves update to Victoza label

FPR2 targeting controls neuroinflammation and oxidative stress in vitro

Shanghai Fochon Pharmaceutical and Fochon Pharma patent SLC22A12 inhibitors

FDA grants priority review to Repatha sBLA seeking to include cardiovascular data

Esteve divulges dual sigma1 and mu-opioid receptor ligands

Servier exercises option to license novel osteoarthritis molecule GLPG-1972 from Galapagos

TNF-alpha production inhibitors disclosed at Kangpu Biopharmaceuticals

Les Laboratoires Servier discovers carboxypeptidase B2 inhibitors

FDA awards fast track designation to Eiger's pegylated interferon lambda 1a

ATR kinase inhibitors identified at Bayer Pharma

Tesaro and Takeda sign niraparib licensing agreement for Japan

Pfizer discloses dopamine D3 receptor ligands

Phase III study of dusquetide for oral mucositis in head and neck cancer patients begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...